These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 25017254)
1. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer. Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243 [TBL] [Abstract][Full Text] [Related]
3. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426 [TBL] [Abstract][Full Text] [Related]
4. Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. Dong M; Wan XB; Yuan ZY; Wei L; Fan XJ; Wang TT; Lv YC; Li X; Chen ZH; Chen J; Lin Q; Wen JY; Ma XK; Liu Q; Wu XY Med Oncol; 2013 Mar; 30(1):355. PubMed ID: 23408367 [TBL] [Abstract][Full Text] [Related]
5. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Dales JP; Garcia S; Meunier-Carpentier S; Andrac-Meyer L; Haddad O; Lavaut MN; Allasia C; Bonnier P; Charpin C Int J Cancer; 2005 Sep; 116(5):734-9. PubMed ID: 15849727 [TBL] [Abstract][Full Text] [Related]
8. Expression of LPA2 is associated with poor prognosis in human breast cancer and regulates HIF-1α expression and breast cancer cell growth. Li M; Xiao D; Zhang J; Qu H; Yang Y; Yan Y; Liu X; Wang J; Liu L; Wang J; Duan X Oncol Rep; 2016 Dec; 36(6):3479-3487. PubMed ID: 27805252 [TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. Chai CY; Chen WT; Hung WC; Kang WY; Huang YC; Su YC; Yang CH J Clin Pathol; 2008 May; 61(5):658-64. PubMed ID: 17908805 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer. Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245 [TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259 [TBL] [Abstract][Full Text] [Related]
13. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Schoppmann SF; Fenzl A; Schindl M; Bachleitner-Hofmann T; Nagy K; Gnant M; Horvat R; Jakesz R; Birner P Breast Cancer Res Treat; 2006 Sep; 99(2):135-41. PubMed ID: 16555123 [TBL] [Abstract][Full Text] [Related]
15. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051 [TBL] [Abstract][Full Text] [Related]
17. Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Kuijper A; van der Groep P; van der Wall E; van Diest PJ Breast Cancer Res; 2005; 7(5):R808-18. PubMed ID: 16168127 [TBL] [Abstract][Full Text] [Related]
18. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043 [TBL] [Abstract][Full Text] [Related]
19. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757 [TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]